Bladder Dysfunction in Advanced Stages of MS
While the spastic bladder is still quite accessible to drug therapies, more complex bladder dysfunctions, which mainly characterize later stages of MS, are no longer so easy to treat.
Continue reading
Bladder Dysfunction: The Spastic Bladder – A Common Problem in Early MS
Bladder dysfunction is among the most common and perhaps also the most underestimated symptoms of MS. It can be assumed that up to 80% of those affected by MS develop problems with the bladder during
Continue reading
Pregnancy under Tysabri therapy – how should one proceed?
I had already written about the topic of pregnancy in women with mild/moderate MS in the context of this blog. In doing so, I had excluded women with highly active MS – so explicitly also
Continue readingExtending the Infusion Intervals of Tysabri – a Sensible Measure in MS?
Tysabri (active ingredient Natalizumab) is given for (highly-) active Multiple Sclerosis every 4 weeks. Recently, it has been frequently mentioned that extending the infusion interval – often the number 8 weeks is mentioned – reduces
Continue reading
Melatonin and MS
The results on melatonin and MS are interesting from my point of view, mainly because they show us how complex the interaction between environmental factors and the development or course of MS is – and
Continue reading
Minocycline – what’s it all about?
It was criticized that I selected the study data on Ocrelizumab as my personal highlight of the last ECTRIMS meeting and did not dedicate a single line to the data on Minocycline. I would like
Continue reading
Pegylated Interferon-beta – an interesting alternative for the basic therapy of MS
Nowadays, multiple sclerosis is primarily treated with oral medications such as dimethyl fumarate or teriflunomide in many cases. The interferon preparations, which were the standard in basic therapy for many years, have a bad reputation
Continue reading
News from ECTRIMS
The annual ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) conference took place during the second week of October. Over 9,000 clinical and scientific MS experts from all regions of the world gathered
Continue reading
Sleep Disorders in MS
The sleep of MS patients is rather less discussed in practice – although sleep disorders are a problem not to be underestimated and are probably more common than is generally assumed. Therefore, I would like
Continue reading
Pharmacological Therapy of Spasticity
Spasticity is a symptom many MS patients suffer from. But what is spasticity exactly? It is not so easy to explain in a few words: Spasticity results from the disinhibition of reflex arcs due to
Continue reading
